Public release date: 25-Jan-2013 [ | E-mail | Share ] Contact: Kathleen Eggleson keggleso@nd.edu 574-631-1229 University of Notre Dame Every day scientists learn more about how the world works at the smallest scales. While this knowledge has the potential to help others, it's possible that the same discoveries can also be used in ways that cause widespread harm. A new article in the journal Nanomedicine, born out of a Federal Bureau of Investigation workshop held at the University of Notre Dame in September 2012, tackles this complex "dual-use" aspect of nanotechnology research. "The rapid pace of breakthroughs in nanotechnology, biotechnology, and other fields, holds the promise of great improvements in areas such as medical diagnosis and treatment" says Kathleen Eggleson, a research scientist in Notre Dame's Center for Nano Science and Technology and the author of the study. "But the risk of misuse of these breakthroughs rises along with the potential benefit. This is the essence of the 'dual-use dilemma.'" The report examines the potential for nano-sized particles (which are measured in billionths of a meter) to breach the blood-brain barrier, the tightly knit layers of cells that afford the brain the highest level of protectionfrom microorganisms, harmful molecules, etc.in … Continue reading →

NOT FOR DISTRIBUTION IN THE USA, CANADA, JAPAN, OR AUSTRALIA Berlin, Germany, January 25, 2013 - MagForce AG (Frankfurt, XETRA: MF6), a leading medical technology company in the field of nanomedicine in oncology, announced today that the Company`s Shareholders` Meeting, which took place earlier in the day, approved all agenda items with a majority of votes. With immediate effect, the Company`s share capital can therefore be increased by up to 18.6 million against cash and noncash contributions, granting preemptive rights to shareholders. The new shares with a notional value of 1.00 will be issued for 1.80. The Company was also granted the right to issue new shares at the issue price of 1.80 per share to certain creditors against noncash contributions to the extent that shareholders` preemptive rights are disapplied for shares counting as fractions or that preemptive rights have not been exercised following the expiration of the subscription period for all shareholders, but only up to a maximum of 8,933,643 new shares. The preemptive rights will not be traded on the stock exchange. In the short to medium term, MagForce will use part of these cash funds to finance the post-marketing glioblastoma study. As well as financing its operating … Continue reading →

Regulatory News: NANOBIOTIX (Euronext: NANO ISIN: FR0011341205), a French company pioneer in nanomedicine developing NanoXray, a revolutionary therapeutic approach to local cancer treatment, today announces its revenues for the 4th quarter and full year 2012. Quaterly revenues and for 2012 * in 2011 the Company recorded no revenue In the 4th quarter of 2012, the Companys revenues came to 46,409, which corresponds to the pro rata share, over such quarter, of the 810,640 upfront paymentreceived within the framework of a license contract with PharmaEngine for the Asia-Pacific region. The revenue is comparable to the one recorded over the 3rd quarter 2012, totaling 74,153 over the year. This amount is in line with the Companys strategic plan; its business model being based on the commercialization of NBTXR3, which implies to first focus on the products development and clinical approval by the relevant authorities. Public funding for research expenditures, which comprises research tax credit, is not included in the revenues but is part of the Companys operating revenues, released with half and full year results. As a reminder, since the Companys IPO on the regulated market of NYSE Euronext in Paris, several major events have marked the end of the year: Next … Continue reading →